{
    "clinical_study": {
        "@rank": "149684", 
        "arm_group": [
            {
                "arm_group_label": "Nephropathy", 
                "arm_group_type": "Experimental", 
                "description": "Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether a diuretic drug called amiloride is capable\n      of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients\n      with kidney disease. Our hypothesis states that amiloride is capable of reducing blood\n      pressure in these patients and thus decrease the cardiovascular risk associated with\n      diabetic kidney disease."
        }, 
        "brief_title": "Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease", 
        "condition": [
            "Diabetic Nephropathies", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Nephropathies", 
                "Hypertension", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Negative pregnancy test at inclusion and taking contraceptive medication\n\n          -  One group with diabetic nephropathy and overt proteinuria\n\n          -  One normoalbuminuric group without nephropathy\n\n          -  Creatinine clearance > 40 ml/min\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes\n\n          -  Receiving amiloride, glucocorticoids, aldosterone or spironolactone\n\n          -  Clinically relevant organic or systemic disease including malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918488", 
            "org_study_id": "2013-052", 
            "secondary_id": "13-04-R94-A4513-22770"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Nephropathy", 
                    "Control"
                ], 
                "description": "200 mmol NaCl per day given as three meals daily for 4 consecutive days.", 
                "intervention_name": "Standardized salt diet", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Nephropathy", 
                    "Control"
                ], 
                "description": "Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.", 
                "intervention_name": "Amiloride", 
                "intervention_type": "Drug", 
                "other_name": "Triamterene"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amiloride", 
                "Sodium Channel Blockers", 
                "Triamterene"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic Nephropathies", 
            "Hypertension", 
            "Proteinuria", 
            "Albuminuria", 
            "Epithelial Sodium Channels", 
            "Epithelial Sodium Channel Blockers", 
            "Amiloride"
        ], 
        "lastchanged_date": "October 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "zip": "DK-5000"
                }, 
                "name": "Cardiovascular and Renal Research"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy", 
        "overall_official": [
            {
                "affiliation": "University of Southern Denmark", 
                "last_name": "Henrik Andersen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Odense University Hospital", 
                "last_name": "Jan Erik Henriksen, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Odense University Hospital", 
                "last_name": "Claus Bistrup, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Southern Denmark", 
                "last_name": "Boye L Jensen, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Denmark: The Regional Committee on Biomedical Research Ethics", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24-hour urinary sodium excretion induced by amiloride", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline urinary sodium excretion at 24 hours after amiloride administration"
        }, 
        "reference": [
            {
                "PMID": "19073825", 
                "citation": "Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, Stubbe J, Jensen ON, Thiesson HC, Uhrenholt TR, Jespersen B, Jensen BL, Korbmacher C, Sk\u00f8tt O. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol. 2009 Feb;20(2):299-310. doi: 10.1681/ASN.2008040364. Epub 2008 Dec 10."
            }, 
            {
                "PMID": "19793956", 
                "citation": "Svenningsen P, Uhrenholt TR, Palarasah Y, Skj\u00f8dt K, Jensen BL, Sk\u00f8tt O. Prostasin-dependent activation of epithelial Na+ channels by low plasmin concentrations. Am J Physiol Regul Integr Comp Physiol. 2009 Dec;297(6):R1733-41. doi: 10.1152/ajpregu.00321.2009. Epub 2009 Sep 30."
            }, 
            {
                "PMID": "16116042", 
                "citation": "Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005 Sep;46(3):481-7. Epub 2005 Aug 22. Review."
            }, 
            {
                "PMID": "22987920", 
                "citation": "Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-M\u00f8ller B, Jespersen B, Bistrup C, Jensen BL. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension. 2012 Nov;60(5):1346-51. doi: 10.1161/HYPERTENSIONAHA.112.198879. Epub 2012 Sep 17."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918488"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Southern Denmark", 
            "investigator_full_name": "Henrik Andersen, MD", 
            "investigator_title": "MD, PhD student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Office blood pressure measurements", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline office blood pressure at day 4 of salt diet and at 24 hours after amiloride administration"
        }, 
        "source": "University of Southern Denmark", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Odense University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Region Southern Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ministry of Science, Innovation and Higher Education (Denmark)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Danish Heart Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Southern Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}